India is backing patient-specific 3D-printed bone grafts as an import-substitution technology

The Technology Development Board under the Department of Science and Technology has extended financial assistance to Ceramat Private Limited in Palghar, Maharashtra, for commercialisation of standard and patient-specific calcium-phosphate bone grafts. The project will use both Digital Light Processing and extrusion-based 3D-printing techniques.

Materials such as hydroxyapatite and beta-tricalcium phosphate are used in bone-graft applications because their mineral chemistry resembles components of natural bone. Ceramat already makes conventional graft materials; the supported project is intended to add digitally designed, customised structures matched to individual clinical requirements.

The policy angle is import substitution in advanced medical technology. But commercialisation support should not be confused with proof of clinical superiority or nationwide deployment. Regulatory compliance, manufacturing consistency, clinical validation, cost and physician adoption will determine how far an indigenous technology moves from supported project to routine healthcare use.